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1Società Italiana Studi di Medicina della Riproduzione, S.I.S.Me.R. Reproductive Medicine Institute, Bologna, Emilia-Romagna, Italy
2Obstetrics and Gynecology Department, Koc University, Istanbul, Turkey 3Reproductive Medicine, Sahlgrenska University Hospital,
Gothenburg, Sweden 4Fertility Europe Evere, Evere, Belgium 5Department of Obstetrics and Gynaecology, University of Helsinki and
Helsinki University Hospital, Helsinki, Finland 6Department of Obstetrics and Gynaecology, University of Oulu, Oulu University Hospital
and Medical Research Centre, PEDEGO Research Unit, Oulu, Finland 7ESHRE Central Office, Grimbergen, Belgium 8Reproductive
Medicine Service, Dexeus Mujer, Hospital Universitari Dexeus/Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, Barcelona Stem Cell
Bank, Regenerative Medicine Programme, Barcelona, Spain 9Rotunda Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland
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ABSTRACT: The coronavirus disease 2019 (COVID-19) pandemic created a significant impact on medically assisted reproduction (MAR)
services. ESHRE decided to mobilize resources in order to collect, analyse, monitor, prepare and disseminate severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) knowledge specifically related to ART and early pregnancy. This article presents the impact of the
SARS-CoV-2 pandemic focusing on reproductive healthcare. It details the rationale behind the guidance prepared to support MAR
services in organizing and managing the re-start of treatments or in case of any future wave of COVID-19 disease. The guidance includes
information on patient selection and informed consent, staff and patient triage and testing, adaptation of ART services, treatment planning
and code of conduct. The initiatives detailed in this article are not necessarily COVID-specific and such action plans could be applied
effectively to manage similar emergency situations in different areas of medicine, in the future.
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Introduction
The seriousness of the severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) pandemic and the unprecedented measures taken by
governments to prevent the spread of disease and protect the popula-
tion has impacted the way medical care is accessed and delivered.
During the outbreak, medically assisted reproduction (MAR) services
were curtailed or, in many cases, completely stopped to protect
patients and staff and to avoid further stress for strained healthcare
systems (Coronavirus COVID-19: ESHRE statement on pregnancy and
conception. 19 March 2020. https://www.eshre.eu/COVID19WG).
To face this new scenario, ESHRE mobilized resources in order to
collect, analyse, monitor, prepare and disseminate SARS-CoV-2
knowledge specifically related to ART and early pregnancy (https://
www.eshre.eu/COVID19WG). This article presents the initiatives
undertaken by ESHRE and details the guidance prepared to support
MAR services in organizing and managing the re-start of treatments or
in case of any future wave of the disease.
SARS-CoV-2 pandemic
SARS-CoV-2 infection was declared a pandemic by the World Health
Organization on the 11th March 2020, 3 months after the first accounts
from the Hubei region of China. The rapid progress of the disease re-
quired the development of strategies such as isolation of individuals
and extensive use of personal protective equipment (PPE) to delay the
effects of SARS-CoV-2 in the general population.
In order to increase effectiveness, the list of preventative measures
advanced to the lockdown of a very large proportion of economic ac-
tivities such as travel, education and non-urgent services. Likewise,
hospitals curtailed elective surgery and clinical throughput, and diverted
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their resources to the most essential care for the waves of patients
suffering from coronavirus disease 2019 (COVID-19).
Despite global efforts, as of the 30th August 2020, more than
25 million individuals were confirmed to have been infected and more
than 840 000 lost their lives due to the disease.
SARS-CoV-2 causes fever, dry cough, tiredness, sore throat, loss of
taste or/and smell, shortness of breath, diarrhoea and conjunctivitis.
Like SARS-CoV and Middle East respiratory syndrome-CoV,
SARS-CoV-2 infection can lead to lethal pneumonia, yet, contrarily to
previous viruses, it has a stronger human-to-human transmission
(Wrapp et al., 2020; Wu, 2020). The primary route of SARS-CoV-2
transmission is through respiratory droplets from infected persons
who are often asymptomatic and, as the incubation time may vary, the
contagiousness of the disease is especially insidious.
For SARS-CoV-2 to mediate entry into host cells, the spike protein
specifically recognizes the angiotensin-converting enzyme 2 (ACE2) as
its receptor (Li et al., 2020b; Xu et al., 2020). The ACE2 receptor is
present in many human tissues, including testis, ovary, vagina
and uterus, although, at the moment, there is no clear evidence of its
presence in gametes (Hikmet et al., 2020; Li et al., 2020b).
The lungs are the organs most affected by COVID-19, with respira-
tory failure developing and causing death in severe cases. Respiratory
impairment can also occur if the virus affects the central nervous
system (Asadi-Pooya and Simani, 2020; Li et al., 2020c).
Owing to recent identification of this disease, at present there are
no established specific treatments and several potential options are
being tested. Prevention is currently the most effective strategy to
contain the disease.
The effect of COVID-19 on reproductive
healthcare
Reproductive medicine centres have a high concentration of staff
members owing to the multidisciplinary expertise required. To opti-
mize efficacy and efficiency, patients are treated according to tight
schedules by teams of professionals that very often overlap their shifts.
In March–April 2020, during the pandemic escalation, most MAR
centres around the world reduced numbers of, or even stopped, their
routine activities with the aim of minimizing the risk of infection and to
comply with governmental decisions to social distance. Patients’ and
professionals’ anxiety was increased by the lack of specific evidence on
viral aggressiveness and potential vertical transmission. It still remains
unknown if the virus has any effect upon the embryo in vivo and
in vitro. As regards vertical transmission, while some initial papers of-
fered reassurance (Chen et al., 2020; Liu et al., 2020,, the case for is
becoming stronger lately (Deniz and Tezer, 2020). Last but not least,
in many ART units attached to hospitals, ventilators, ultrasound equip-
ment and staff were diverted to COVID-19 wards, leaving ART units
unable to deliver full service. For these reasons, the impact in the
MAR field was dramatic and widespread.
ESHRE’S contribution on guidance for
patients and professionals
ESHRE produced its first recommendation related to the practice
of ART during the emergence of the pandemic on 19th March
2020 (Coronavirus COVID-19: ESHRE statement on pregnancy and
conception. 19 March 2020. https://www.eshre.eu/COVID19WG).
Subsequently, an ESHRE COVID-19 Working Group (WG) was
established, tasked to monitor and inform its members, the scientific
community and patients on the development of the pandemic and its
impact upon ART services.
During the pandemic escalation (Phase 1), the WG collected scientific
evidence, and released a recommendation to discontinue all routine
MAR activities (except fertility preservation for medical reasons)
(https://www.eshre.eu/COVID19WG). When the disease spread
slowed, the WG disseminated the ‘ESHRE Guidance on recommencing
ART treatments’, whose rationale and content are detailed below. In
addition, a questionnaire was forwarded to ESHRE National
Representatives to assess MAR activities in Europe, with results
showing that treatments were completely or partly suspended in the
majority of European countries from March to April, and resuming as of
May 2020 (The ESHRE COVID-19 Working group et al., 2020). Finally,
the WG solicited and promoted the reporting of cases aimed at investi-
gating the potential effects of SARS-CoV-2 on MAR pregnancies.
Clinicians and scientists are encouraged to submit their case reports
through the dedicated platform at https://nl.surveymonkey.com/r/
COVID19ART. This last initiative was implemented to collect evidence
on the impact of SARS-CoV-2 upon the first and second trimester of
pregnancy as, to date, the published data are limited to third-trimester
pregnancies and/or deliveries (Rasmussen et al., 2020; Schmid et al.,
2020; Schwartz, 2020; Schwartz and Graham, 2020; Liu et al., 2020).
ESHRE’s effort was not singular, as other Societies have published
COVID-19 recommendations. Of relevance is that ESHRE and two
other global societies, namely the American Society for Reproductive
Medicine and the International Federation of Fertility Societies, jointly
offered solutions to the challenges of COVID-19 impact upon the
provision and access to infertility treatment (Veiga et al., 2020).
ESHRE guidance on
recommencing ART treatments
While MAR services were suspended, no government or scientific
society recommended postponing spontaneous pregnancies because
of the COVID-19 pandemic.
Following an initial MAR activity suspension, a gradual re-start of
activities occurred from May 2020. ESHRE guidance is based on the
principle that maintaining safety requires careful and sustained planning.
Generally speaking, ART activities are strictly regulated and subject to
high standards of safety and quality (De los Santos et al., 2016).
However, the SARS-CoV-2 pandemic required specific preventative
measures to minimize the risk of infection during ART procedures.
Taking into consideration the local, national and governmental guid-
ance/recommendation related to COVID-19 and the principles of
good clinical and laboratory practice, a comprehensive safety plan
must be implemented, based on the following pillars:
• Discussion, agreement and consent to start treatment
• Staff and patient triage
• Access to advice and treatment
• Adaptation of ART services
• Treatment cycle planning
• Code of Conduct for staff and patients































































































.Discussion, agreement and consent to start
treatment
Adequate patient selection means not only preventing the possibly
infected and undiagnosed patients from attending the services but also
advising patients with a higher risk of developing severe disease to
postpone treatment. Patients suffering from systemic pathologies, such
as diabetes, hypertension, heart, lung and liver or kidney disease, those
using immunosuppressant therapy (i.e. post-transplant patients) should
first be referred to expert healthcare professionals for assessment of
their clinical situation and evaluation of the option of starting treat-
ments at a safer time.
The risk reduction and treatment information offered to patients
must be fully delivered and understood, including the balance between
risks and benefits if the treatment is postponed. A specific code of
conduct including the moral obligation to immediately inform the treat-
ing staff if the information previously provided is no longer valid, or if
symptoms arise, should be clearly detailed and agreed upon. This doc-
ument should also contain a section aimed at raising awareness for rel-
atives and friends about how and why infection could jeopardize a
couple’s treatment.
Worthy a special mention are patients who developed the severe
form of COVID-19 disease and required ventilation. Such patients
should be considered a high-risk group as severe and permanent lung
impairment occurs (Salehi et al., 2020). To avoid potential complica-
tions during anaesthesia and pregnancy, assessment of respiratory
function should be carried out before proceeding with ART.
Last but not least, patients wishing to postpone the treatment for
personal reasons or owing to safety concerns should be supported in
their decision. All ART treatments are at patient request.
Staff and patient triage
All individuals planning to enter the MAR centre (irrespective of being
staff, patients or accompanying persons, cleaners and auxiliary services,
including contractors) are potentially susceptible of carrying the SARS-
CoV-2 virus and may spread the disease. The incubation time for
COVID-19 is variable (Sethuraman et al., 2020) and asymptomatic
individuals could pass on the virus to patients or staff members. For
this reason, triage regarding health status, symptoms and lifestyle of
patients, staff members and individuals living in the same household
should be routine before attending the MAR centre.
Triage is a useful tool for early detection of people at risk of infec-
tion or of potentially infected individuals, facilitating referral for further
diagnostic assessment. For this reason, the triage questionnaire should
be clear and detailed, and it should be updated based on evolving evi-
dence. Patient triage is an essential step in management, as few cases
are diagnosed positive after a negative triage questionnaire (González-
Ravina et al., 2020). The triage principle is summarized in Fig. 1.
Triage of staff
All staff members should fill in the triage questionnaire and preferably
be SARS-CoV-2 tested 15 days before activities re-start. Re-triage
should occur on a regular basis according to local prevalence of dis-
ease, prevalence of triage positivity and test availability. Any staff mem-
ber that suspects she/he might be infected or is symptomatic should
immediately notify the centre and undergo SARS-CoV-2 testing. A sec-
ond confirmation test might be required. Staff members who test
positive for IgM antibodies and/or by PCR (irrespective of symptoms)
are potentially infectious and should receive health advice while under-
going self-quarantine. Documented clearance of the infection by RT-
PCR or other test (IgG-IgM) is required to resume work.
Triage of patients
All patients planning to start an ART treatment should undergo triage,
aiming to identify individuals with a high risk of being affected and
spreading the SARS-CoV-2 infection.
Both partners should fill in the questionnaire 2 weeks before the
treatment start date and every 2 weeks during treatment. Any changes
in the information provided in the questionnaire should be immediately
notified to the MAR centre.
Based on the answers provided, triage procedures can result in the
following scenarios (Fig. 2):
• Scenario 1
If both patients are asymptomatic and triaged as low risk (negative
clinical history, lifestyle and no contact with potentially infected
people), the couple should be accepted for treatment.
• Scenario 2
This scenario applies to patients who recovered from a previous
COVID-19 infection and to those who develop symptoms before
starting or during the treatment. Patients who suffered with and re-
covered from COVID-19 should provide evidence of clearance and
undergo IgM/IgG testing in order to be considered for treatment.
In this case, additional tests or specific medical assessment could be
requested to evaluate potential consequences of the disease as a
further risk factor for the patient.
If one or both partners develop symptoms before starting the
treatment, triage should be repeated at the beginning of ovarian
stimulation. If this triage is negative, patients can proceed with
the treatment. If symptoms persist, diagnostic testing should be
performed. Based on the result it will be decided whether to
continue treatment (negative test) or to postpone it (positive
test).
If one or both partners develop symptoms during ovarian stimulation,
testing should be performed. Based on the result it will be decided
whether to continue treatment (negative test) or to postpone it
(positive test).
• Scenario 3
If one or both partners are symptomatic, triaged as high risk, and/
or tested SARS-CoV-2 IgM or RT-PCR positive, treatment should
be postponed.
If patients test positive (IgM or RT-PCR), irrespective of the scenario,
test performed or symptoms, they should be regarded as infectious
and referred to dedicated services in compliance with local and na-
tional guidance.
Good practice dictates that patients should be followed-up 3 weeks
after oocyte retrieval (OR)/embryo transfer (ET), even if a pregnancy
was not achieved, to check the state of their health and identify poten-
tial positive cases. Contact tracing measures will be activated where a
post-treatment positive case is diagnosed.





























RT-PCR: presence of virus
The identification of the SARS-CoV-2 virus presented the initial chal-
lenge during the pandemic, echoing the alarms that Dawson raised
only 6 months previously (Dawson et al., 2019). RT-PCR is the most
common method for SARS-CoV-2 detection. Both oropharyngeal
(OP) and nasopharyngeal (NP) swabs have been most frequently used
for diagnosis (Wang et al., 2020a).
Lately, evidence shows NP swabs to be the preferred sampling
methodology (Wang et al., 2020b): the authors reviewed the results
of simultaneous, separate NP (single nostril) and OP (both throat
sides) swabbing from 353 patients presenting with symptoms. They
showed that OP swabs on their own have a much lower detection
rate compared to NP swabs and that 73.1% of NP positive cases
were negative by OP swab, indicating false-negative results may occur
using an OP swab only approach. They concluded that OP swabs may
result in a worryingly high false-negative rate.
Multiple RT-PCR protocols have been proposed. Initial protocols
used were based on the E gene and RdRp gene (Corman et al., 2020),
yet some authors pointed out the limitations of the existing E gene as-
say, which showed high background levels hampering a clear evaluation
of the assays (Konrad et al., 2020). The Centers for Disease Control
and Prevention recommends targeting the N gene (Centers for
Disease Control and Prevention, 2020).
As regards sensitivity and specificity of RT-PCR, a recently published
paper (van Kasteren et al., 2020) showed the positive identification
Figure 1. Triage system aimed at identifying potentially infected/infected patients in order to manage subsequent access to
medically ART. Adapted from Giordano et al. (2020).
Figure 2. Summary of potential scenarios after triage and of subsequent approaches to be adopted. COVID-19: coronavirus disease 2019.
































































































rate to fluctuate from 10/13 to 13/13 and that specificity appears to
be 100%, all kits showing no cross-reactivity with other Coronaviruses.
An important question nevertheless remains: when, during the early
days of infection, can we optimally detect the virus? Kucirka et al.
(2020) showed that during the 4 days of asymptomatic infection, the
probability of a false-negative result decreased from 100% on Day 1 to
68% on Day 4. On the day of symptoms onset, the median false-
negative rate was 38%. This decreased to 20% on Day 8 (3 days after
symptom onset) then began to increase again, from 21% on Day 9 to
66% on Day 21. The false-negative rate was minimized 3 days after the
onset of symptoms, on average. As such, this may be the optimal time
for testing if the goal is to minimize false-negative results (Kucirka
et al., 2020).
At this moment, it is clear that RT-PCR testing is not 100% accurate
and that risk factors, clinical presentation and symptoms must all be
considered, particularly where the triage is positive, and the testing is
negative (Bullis et al., 2020; Feng et al., 2020).
IgM/IgG: immune response of a person exposed
IgM/IgG presence reflects an individual’s immune response to viral
exposure, and such testing should be considered complementary to
triage.
Two recent papers provided an insight into the anti-SARS-CoV-2
antibody behaviour. Long et al. (2020) reported that 100% of patients
tested positive for antiviral IgG within 19 days after symptoms onset
and that seroconversion for IgG and IgM occurred simultaneously or
sequentially. Sethuraman et al. (2020) observed that IgM and IgG sero-
conversion occurred in all patients between the third and fourth week
of clinical illness. IgM begins to decline and almost disappears by week
7, while IgG persists beyond 7 weeks.
Considering the rate of RT-PCR false-negative results, particularly in
the early stages of the disease (first 4 days of infection) (Kucirka et al.,
2020), the use of serological testing to complement swabs might
increase detection rates, as antibodies show up as early as Days 2–4
after symptom onset (Long et al., 2020). In the case of negative
RT-PCR testing, the use of IgG and IgM may facilitate a better under-
standing of the diagnosis (the status) and appropriate allocation to
proceed with or postpone treatment. Ultimately, local, regional and
national guidelines on testing should be observed.
Access to advice and treatment
Patient and staff information and education on COVID-19 is a neces-
sary requirement for admission for treatment and work attendance,
respectively. More specifically, both groups should be instructed on
the use of PPE, on the importance of social distancing, and on other
preventative measures before, during and after treatment. Information
on COVID-19 symptoms, SARS-CoV-2 transmission and implications
should also be provided in a clear and comprehensive way. Finally,
patients should acknowledge that treatment will be discontinued if
their status changes from low to high risk.
Adaptation of ART services
ART units should be re-organized to ensure social distancing is
respected. Routine sanitation of all areas should be performed, and
specific COVID-19 sanitation procedures should be implemented in
case of positive patients and/or staff members. Patient management
and staff work shifts should be re-thought and adapted to the high-risk
pandemic situation. Specific COVID-19 training and procedures should
be put in place, and staff working patterns and planning should con-
sider the creation of mini teams.
Also, remote access procedures should be encouraged. Whenever
possible, telemedicine should be used to reduce physical contact be-
tween staff and patients. The number of people simultaneously pre-
sent in the centre should be limited by managing appointments
according to specific timetables and by restricting access for accompa-
nying persons (including partner if her/his presence is not strictly nec-
essary). Waiting areas should be re-designed to guarantee social
distancing and protective screens for administrative staff installed. PPE
and sanitation devices should be at disposal of patients and staff. In or-
der to avoid discontinuation of treatments, agreements between MAR
centres for the management of potential emergency closures due to
COVID-19 cases are strongly recommended.
Treatment cycle planning
Staff members should use appropriate PPE at all times. When showing
signs of infection, individuals should be isolated and tested, while
patients should be carefully monitored to detect symptoms. In this
case, specific action (further testing, postponement of treatment, etc.)
should be taken accordingly. Procedures to be adopted should be
based on triage results (Fig. 3).
Ovarian stimulation monitoring
Each centre should adapt its activity to physical capacity and staff avail-
ability aiming to ensure social distancing and respect for national guid-
ance on reducing risk of COVID-19. It is recommended to start small
and increase the numbers only when the professionals become confi-
dent that measures in place are working. Further adaptation includes
streamlining appointments to facilitate social distancing, reducing wait-
ing time, scanning and blood testing and facilitating a very quick turn-
around time. Ultrasounds and blood tests could be limited to two or
three tests (depending on protocol used), respectively, at down-
regulation, during stimulation and on the day of trigger, unless clinical
reasons dictate otherwise. Specific attention should be paid to hygiene
of ultrasound equipment, all medical devices used and consultation
rooms.
All follow-up advice and information can be given via phone or
video conferencing.
Oocyte retrieval
If both partners are asymptomatic and triaged negative (Scenario 1),
standard procedures should be adopted, unless symptoms arise
between ovulation trigger and OR.
If the re-triage is positive for one or both partners (Scenario 2) fur-
ther testing is recommended (IgM/IgG or RT-PCR). Whether to con-
tinue or to postpone treatment will be decided based on the results.
If one or both partners are triaged or tested positive (Scenario 3)
before ovulation triggering or embryo thawing, the treatment should
be immediately postponed, and the positive patient should be isolated
and referred to dedicated services.
Exceptional measures should be applied in case of positive patients
who cannot postpone treatment (high risk of ovarian hyperstimulation
syndrome, fertility preservation for medical reasons, etc.). In these
cases, OR can be performed by adopting procedures that reduce the
















































.risk of transmission to staff members and other patients. Great atten-
tion must be paid to PPE correct use. The operating theatre and the
lab should be accurately disinfected and sanitized immediately after the
procedure. Considering the risks of horizontal transmission, switching
from aerosol generating general anaesthesia to i.v. sedation or local an-
aesthesia may also be considered.
Laboratory practice, ET and cryopreservation
The ART laboratory should adhere to established good laboratory
practice guidelines (De los Santos et al., 2016) to ensure safety and
quality of tissues and cells. In the circumstances of the COVID-19
pandemic, extra caution is required to avoid potential SARS-CoV-2
infections through processing of follicular fluid and semen samples
(Li et al., 2020a). Native follicular fluid and seminal plasma should be
diluted and safely disposed of, in individual closed containers.
Consideration must be also given to gamete and tissue cryopreser-
vation during the COVID-19 pandemic as the stored material could
potentially be contaminated with the virus (Yakass and Woodward,
2020).
If a patient becomes positive after OR, all oocytes/embryos should
be cryopreserved using high security straws and/or vapour phase stor-
age tanks. ET should be performed only in case of low-risk and asymp-
tomatic couples. Partners should not be allowed in the operating
theatre during ET.
With reference to work organization, staff should be sub-divided in
mini teams to guarantee continuity of treatment and reduce
unnecessary exposure. The size of the team and the timetable (daily,
three daily or weekly rotation) is dependent on the number of patients
treated and the number of staff in the centre. Each centre must per-
form due diligence by involving all staff in this decision process. The
principle is that only the minimum number of staff needed should be
present at any one time.
Code of Conduct for staff and patients
A Code of Conduct is a new concept in a crisis situation like the
COVID-19 pandemic. It is underpinned by the ‘all for one, one for all’
principle. Only through collaboration and trust can a safe continuation
or restart of activities be achieved. Collaboration and trust between
patients and healthcare professionals remain essential elements of any
medical treatment. An individual sense of responsibility is of utmost
importance to prevent potential cases of infection for both patients
and MAR centre staff members.
The first step in establishing the Code is educating all staff and
patients in relation to SARS-CoV-2. This is followed by specific recom-
mendations in relation to engaging with the outside world, such as
hygiene, awareness of risk and self-imposed measures, to reduce the
risk of infection. Ideally, each centre details what restrictions they wish
their staff and patients to follow. Understandably, this document would
need to be in line with national recommendations, proportionate to
the impact of COVID-19 in a certain region and in line with cultural
norms. Therefore, the Code of Conduct should be written within the
Figure 3. Recommended management of patients based on three scenarios following triage.
































































































context of the centre, the patients, the staff, and the evolution of the
pandemic in a specific location. Being extra cautious and meticulous in
social distancing and hand hygiene is certainly advised during therapy.
Both staff and patients should adapt their lifestyle in order to limit the
exposure to risk and they should also inform and ask their friends and
family to respect their shared responsibility in remaining healthy. The
Code of Conduct is, ultimately, an agreement to being and practicing
together in a safe environment.
Acceptance from all parties and continuation of such an agreement
are key to safe provision of care in the MAR centre. Finally, the Code
of Conduct must make it clear that it is a matter of all becoming af-
fected by the consequences of one participant breaking the Code.
Patients and staff members will be asked to fill in and sign regularly a
specific form stating that they are well and that they have complied
with the provisions of the Code of Conduct in the best interest of all
subjects involved. The Code is a matter for each centre to agree with
their staff and their patients.
Conclusions and applicability of
the model to other pandemics
This article deals with the most unusual scenario encountered in living
memory: the halt of global activities due to a severe SARS-CoV-2 pan-
demic with enormous potential for harm. It details the role of ESHRE
as a Scientific Society in the field of Reproductive Medicine and
Science in supporting services and patients during such unprecedented
times and the impact of the pandemic upon ART services in Europe.
A working group was invited to meet weekly in order to offer swift
and timely reactions to the constant evolution of the pandemic and
the related scientific evidence. Actions were taken to collect reliable
data and information and to disseminate them in a clear and compre-
hensive way. Furthermore, the group created a model of adaption of
ART practice to the reality of the pandemic and proposed an original
model for dealing with an emergency situation that has the potential
to paralyse practice globally.
Based on these data and information, recommendations applicable
to different clinical (teaching hospitals, private practices, free-standing
units) and national settings were issued at different time points, at the
beginning and during the pandemic, aiming to support professionals
wishing to re-start activities in a safe manner, once allowed or deemed
appropriate to do so.
The initiatives detailed in this article, while COVID-19 specific, are
applicable to managing similar emergency situations in different areas
of medicine in the future.
In particular, considering the current pandemic trend and the de-
creasing average age of COVID-19 patients, it is reasonable to expect
that increasing numbers of patients undergoing ART are likely to be
infected. Furthermore, detecting them might be challenging because a
high percentage might be asymptomatic. For this reason, MAR
Centres should be especially careful with triage and testing procedures
in the coming months. It is also possible that triage questionnaires
might have to be adjusted accordingly in the near future.
COVID-19 is a systemic disorder affecting many organs. The
long-term multiorgan consequences of an acute SARS-CoV-2 infection
should not be underestimated. In fact, long-term follow-up of
SARS-CoV-2 infected individuals should be a health priority and the
question of a previous COVID-19 event should be part of the history
taking in all chronic diseases. As ACE2 receptors are present in the
reproductive tract, long-term follow-up of patients that developed
COVID-19 could potentially identify new causes of infertility,
SARS-CoV-2 related. Awareness of asking questions related to this in-
fectious agent could become a part of the investigation of the infertile
couple in the future. Through recently established research grants
dedicated to SARS-CoV-2 and reproduction, ESHRE is promoting
long-term research related to this virus and its impact upon women
and men of reproductive age.
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